Clinical trial
A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period
NCT00755950 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period
- Lead sponsor
- University of Maryland, Baltimore
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- October 31, 2008
- Completion date
- December 31, 2015
- Enrollment
- 70 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
acute cmv hepatitis, acute ebv hepatitis, acute hepatitis a, acute hepatitis b, acute hepatitis c, acute hepatitis e